Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have received an average recommendation of "Moderate Buy" from the nine analysts that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $21.38.

YMAB has been the topic of several recent research reports. Canaccord Genuity Group reissued a "buy" rating and set a $26.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Wedbush reissued an "outperform" rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. HC Wainwright reissued a "buy" rating and set a $22.00 price objective on shares of Y-mAbs Therapeutics in a report on Friday, November 15th. Canaccord Genuity Group raised Y-mAbs Therapeutics to a "strong-buy" rating in a report on Tuesday, August 13th. Finally, Morgan Stanley cut their price objective on Y-mAbs Therapeutics from $12.00 to $11.00 and set an "underweight" rating on the stock in a report on Tuesday, August 13th.

Y-mAbs Therapeutics Stock Performance

Shares of NASDAQ YMAB traded down $0.44 during trading hours on Thursday, reaching $10.10. 245,862 shares of the stock were exchanged, compared to its average volume of 330,322. The stock's fifty day simple moving average is $13.82 and its 200 day simple moving average is $12.95. Y-mAbs Therapeutics has a 52 week low of $5.29 and a 52 week high of $20.90. The firm has a market capitalization of $452.38 million, a price-to-earnings ratio of -18.70 and a beta of 0.68.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The company had revenue of $18.46 million for the quarter, compared to the consensus estimate of $23.38 million. During the same quarter last year, the business earned ($0.18) EPS. Research analysts predict that Y-mAbs Therapeutics will post -0.64 EPS for the current fiscal year.

Insider Activity

In related news, insider Thomas Gad sold 30,000 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $12.97, for a total value of $389,100.00. Following the sale, the insider now owns 67,681 shares in the company, valued at approximately $877,822.57. This trade represents a 30.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Joris Wilms sold 5,000 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the sale, the chief operating officer now owns 30,600 shares in the company, valued at $449,514. This trade represents a 14.04 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 100,000 shares of company stock valued at $1,338,100 over the last three months. Corporate insiders own 22.50% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Barclays PLC grew its stake in shares of Y-mAbs Therapeutics by 433.4% in the third quarter. Barclays PLC now owns 69,222 shares of the company's stock worth $910,000 after purchasing an additional 56,244 shares during the last quarter. Empire Financial Management Company LLC bought a new stake in Y-mAbs Therapeutics during the 3rd quarter valued at approximately $210,000. Geode Capital Management LLC boosted its position in Y-mAbs Therapeutics by 6.2% during the 3rd quarter. Geode Capital Management LLC now owns 813,489 shares of the company's stock valued at $10,699,000 after acquiring an additional 47,846 shares in the last quarter. State Street Corp boosted its position in Y-mAbs Therapeutics by 50.4% during the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company's stock valued at $15,909,000 after acquiring an additional 405,169 shares in the last quarter. Finally, Caligan Partners LP boosted its position in Y-mAbs Therapeutics by 105.3% during the 3rd quarter. Caligan Partners LP now owns 1,195,253 shares of the company's stock valued at $15,718,000 after acquiring an additional 613,175 shares in the last quarter. Hedge funds and other institutional investors own 70.85% of the company's stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.